In yesterday’s Wall Street session, Kodiak Sciences Inc. (NASDAQ:KOD) shares traded at $5.90, up 4.42% from the previous session.
As we calculate the median target price by taking the range between a high of $24.00 and a low of $5.00, we find $12.00. Given the previous closing price of $5.65, this indicates a potential upside of 112.39 percent. KOD stock price is now -21.02% away from the 50-day moving average and -27.62% away from the 200-day moving average. The market capitalization of the company currently stands at $327.16M.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Sponsored
Brokers who have rated the stock have averaged $12.44 as their price target over the next twelve months.
With the price target of $24, CapitalOne recently initiated with Overweight rating for Kodiak Sciences Inc. (NASDAQ: KOD). On August 02, 2022, Citigroup Downgraded its previous ‘Neutral’ rating to ‘Sell’ on the stock keeping its target price maintained at $6, while ‘JP Morgan’ rates the stock as ‘Neutral’.
In other news, BORGESON JOHN A., insider sold 2,798 shares of the company’s stock on Jun 17. The stock was sold for $19,642 at an average price of $7.02. Upon completion of the transaction, the insider now directly owns 173,755 shares in the company, valued at $1.03 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 17, See Remarks EHRLICH JASON sold 2,282 shares of the business’s stock. A total of $16,020 was realized by selling the stock at an average price of $7.02. This leaves the insider owning 56,920 shares of the company worth $0.34 million. Insiders disposed of 7,830 shares of company stock worth roughly $46197.0 over the past 1 year. A total of 0.40% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KOD stock. A new stake in Kodiak Sciences Inc. shares was purchased by BRAIDWELL LP during the first quarter worth $5,394,000. RIA ADVISORY GROUP LLC invested $882,000 in shares of KOD during the first quarter. In the first quarter, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP acquired a new stake in Kodiak Sciences Inc. valued at approximately $74,000. PRINCIPAL FINANCIAL GROUP INC acquired a new stake in KOD for approximately $69,000. JEFFERIES FINANCIAL GROUP INC. purchased a new stake in KOD valued at around $66,000 in the second quarter. In total, there are 221 active investors with 81.40% ownership of the company’s stock.
On Monday morning Kodiak Sciences Inc. (NASDAQ: KOD) stock kicked off with the opening price of $5.56. During the past 12 months, Kodiak Sciences Inc. has had a low of $4.90 and a high of $12.80. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.30, and a quick ratio of 8.30. The fifty day moving average price for KOD is $7.47 and a two-hundred day moving average price translates $8.15 for the stock.
The latest earnings results from Kodiak Sciences Inc. (NASDAQ: KOD) was released for Sep, 2022. According to the Biotechnology Company, earnings per share came in at -$1.47, beating analysts’ expectations of -$1.77 by 0.3. This compares to -$1.30 EPS in the same period last year. The company reported revenue of $79.48 million for the quarter, compared to $67.53 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17.68 percent.
Kodiak Sciences Inc.(KOD) Company Profile
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company’s preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
